Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases

  1. Erica A. Moehle,
  2. Jeremy M. Rock,
  3. Ya-Li Lee,
  4. Yann Jouvenot,
  5. Russell C. DeKelver,
  6. Philip D. Gregory,
  7. Fyodor D. Urnov*, and
  8. Michael C. Holmes
  1. Sangamo BioSciences, Inc., Point Richmond Technology Center, 501 Canal Boulevard, Suite A100, Richmond, CA 94804
  1. Communicated by Carl O. Pabo, Harvard Medical School, Boston, MA, December 27, 2006 (received for review November 14, 2006)

Abstract

Efficient incorporation of novel DNA sequences into a specific site in the genome of living human cells remains a challenge despite its potential utility to genetic medicine, biotechnology, and basic research. We find that a precisely placed double-strand break induced by engineered zinc finger nucleases (ZFNs) can stimulate integration of long DNA stretches into a predetermined genomic location, resulting in high-efficiency site-specific gene addition. Using an extrachromosomal DNA donor carrying a 12-bp tag, a 900-bp ORF, or a 1.5-kb promoter-transcription unit flanked by locus-specific homology arms, we find targeted integration frequencies of 15%, 6%, and 5%, respectively, within 72 h of treatment, and with no selection for the desired event. Importantly, we find that the integration event occurs in a homology-directed manner and leads to the accurate reconstruction of the donor-specified genotype at the endogenous chromosomal locus, and hence presumably results from synthesis-dependent strand annealing repair of the break using the donor DNA as a template. This site-specific gene addition occurs with no measurable increase in the rate of random integration. Remarkably, we also find that ZFNs can drive the addition of an 8-kb sequence carrying three distinct promoter-transcription units into an endogenous locus at a frequency of 6%, also in the absence of any selection. These data reveal the surprising versatility of the specialized polymerase machinery involved in double-strand break repair, illuminate a powerful approach to mammalian cell engineering, and open the possibility of ZFN-driven gene addition therapy for human genetic disease.

Footnotes

  • *To whom correspondence should be addressed. E-mail: furnov{at}sangamo.com
  • Author contributions: E.A.M. and J.M.R. contributed equally to this work; E.A.M., J.M.R., P.D.G., F.D.U., and M.C.H. designed research; E.A.M., J.M.R., Y.-L.L., Y.J., R.C.D., and F.D.U. performed research; E.A.M., J.M.R., F.D.U., and M.C.H. analyzed data; and P.D.G., F.D.U., and M.C.H. wrote the paper.

  • Conflict of interest statement: C.O.P. is chair of the Scientific Advisory Board for Sangamo BioSciences, Inc. E.A.M., J.M.R., Y.-L.L., Y.J., R.C.D., P.D.G., F.D.U., and M.C.H. are full-time employees of Sangamo BioSciences, Inc.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0611478104/DC1.

  • Abbreviations:
    ZFN,
    zinc finger nuclease;
    DSB,
    double-strand break;
    HDR,
    homology-directed repair;
    SDSA,
    synthesis-dependent strand annealing.
  • Freely available online through the PNAS open access option.

« Previous | Next Article »Table of Contents
OPEN ACCESS ARTICLE